Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 549 shares of the biopharmaceutical company’s stock after selling 592 shares during the period. GSA Capital Partners LLP’s holdings in Regeneron Pharmaceuticals were worth $270,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in REGN. BlackRock Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 3,331.5% during the 1st quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Regeneron Pharmaceuticals by 74.1% during the 2nd quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares during the last quarter. Janus Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 58.5% during the 1st quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares during the last quarter. Clearbridge Investments LLC increased its holdings in shares of Regeneron Pharmaceuticals by 55.2% during the 1st quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after buying an additional 245,531 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 97.8% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 485,336 shares of the biopharmaceutical company’s stock worth $238,368,000 after buying an additional 239,937 shares during the last quarter. Institutional investors and hedge funds own 67.40% of the company’s stock.

In other news, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 11,000 shares in the company, valued at approximately $4,950,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total transaction of $248,371.94. Following the sale, the senior vice president now owns 9,099 shares in the company, valued at $4,296,456.81. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,468 shares of company stock worth $42,312,448. Insiders own 10.80% of the company’s stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 440.94 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55. The company has a market cap of $46.75 billion, a PE ratio of 44.24 and a beta of 1.62. The stock’s 50 day moving average is $452.90 and its 200 day moving average is $456.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The business’s revenue was up 21.2% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.94 earnings per share for the current year.

REGN has been the subject of a number of research analyst reports. Raymond James Financial, Inc. restated an “outperform” rating and set a $547.00 price objective (up from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Leerink Swann restated an “outperform” rating and set a $573.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Sanford C. Bernstein downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $410.00 to $480.00 in a report on Monday, June 26th. They noted that the move was a valuation call. Finally, BTIG Research restated a “buy” rating and set a $540.00 price objective (up from $480.00) on shares of Regeneron Pharmaceuticals in a report on Friday, June 30th. Three investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $489.92.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by GSA Capital Partners LLP” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://stocknewstimes.com/2017/10/20/regeneron-pharmaceuticals-inc-regn-shares-sold-by-gsa-capital-partners-llp.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply